开发低剂量迪苏尔菲拉姆直肠支架,用于治疗后莱姆病综合征的应用
Beáta-Mária Benkő1, Bálint-Imre Szabó2,3, Szabina Kádár4
1University Pharmacy Department of Pharmacy Administration, Semmelweis University, Hőgyes Endre u. 7-9, 1092 Budapest, Hungary.
Pharmaceutics
|July 30, 2025
概括
这项研究开发了一种新型的迪苏尔菲拉姆直肠 (DIS),用于治疗持续的莱姆病症状. 该配方增强了DIS的溶解性和透性,为治疗后莱姆病综合征 (PTLS) 提供了有前途的替代疗法.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 药用化学 医学化学
背景情况:
- 莱姆氏病通常需要替代疗法,用于持续的症状不响应标准抗生素治疗.
- 酒精成药物迪苏尔菲拉姆 (DIS) 对莱姆病具有潜在的治疗潜力,但它面临着低生物可用性和快速新陈代谢等配方挑战.
- 改善药物输送对于治疗复杂疾病的临床转化至关重要,如治疗后莱姆病综合征 (PTLDS).
研究的目的:
- 开发和优化低剂量迪苏尔菲拉姆直肠支架,用于治疗后莱姆病综合征的潜在使用.
- 通过创新的配方策略,提高二硫的可溶性和透性.
- 在直肠药物输送系统中研究聚乙烯糖醇 (PEG) 和propyl-β-cyclodextrin (HPBCD) 的协同作用.
主要方法:
- 进行了选溶解和透研究,以选择载体和辅助剂.
- 使用环氧德克斯 (CD) 封装来改善疏水性二硫的水溶性.
- 新型配方的表征涉及差异扫描热度计,X射线衍射和红外光谱学.
主要成果:
- 迪苏尔菲拉姆从脂肪中溶解速度缓慢,但随着环德林封装而显著改善.
- 基于聚乙烯糖醇 (PEG) 的支架,在物理混合物中含有环极素,证明了有效的药物溶解.
- 成功开发了一种新型的直肠输送系统,将低剂量迪苏尔菲拉姆与PEG和propyl-β-cyclodextrin (HPBCD) 协同作用矩阵相结合.
结论:
- 在物理混合物中含有迪苏尔菲拉姆和环素的直肠剂型比传统配方具有优势.
- 这种直肠输送系统绕过肝脏的第一通效应,可能减少剂量限制性毒性.
- 开发的配方简化了生产,并加速了用于治疗应用的重新定位的二硫的可用性.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
299
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
299
01:21Drugs for Treatment of Constipation-Predominant IBS
336
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
336
01:29Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
40
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
40
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
203
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
203